We have located links that may give you full text access.
Case Reports
Journal Article
Aspiration thrombectomy with off-label distal access catheters in the distal intracranial vasculature.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia 2017 November
BACKGROUND: As neurointerventionalists aim to treat occlusions in the ever more distal vasculature, off-label catheters (OLCs) have been adapted for aspiration thrombectomy. This may not be without its attendant risks. Recently issued, a letter from the FDA cautioned providers against using OLCs as substitutes for FDA-cleared aspiration thrombectomy catheters, especially in the distal vasculature. In light of this, we evaluated the efficacy and safety of OLCs used for aspiration thrombectomy in the distal vasculature at our institution.
METHODS: We retrospectively queried all patients who underwent thrombectomy at our institution between January 1, 2016 and March 1, 2017. Patients were screened for: (1) occlusion location in the distal vasculature (M2 or more distal) and (2) direct thrombus aspiration attempt with an OLC. Demographic, clinical, and procedural data were recorded.
RESULTS: Eight patients were included for analysis (Table 1). The median admission NIHSS was 17 (IQR 13-23.3). Occlusion locations included left M2 (6/8), right M2 (1/8), and left M3 (1/8). The OLCs employed included the Stryker Catalyst 6 (5/8), Penumbra Velocity (2/8), and the MicroVention Sofia Plus (1/8). Direct thrombus aspiration was successful in 50% (4/8) of cases, though final TICI 2b-3 was achieved in all patients. There were no instances of symptomatic intracranial hemorrhage. Median NIHSS at discharge was 5 (IQR 0.8, 15).
CONCLUSIONS: Aspiration thrombectomy with OLCs may be safe and effective in the distal vasculature. In light of the recent FDA warning regarding their use, further evaluation of OLCs in this capacity is warranted.
METHODS: We retrospectively queried all patients who underwent thrombectomy at our institution between January 1, 2016 and March 1, 2017. Patients were screened for: (1) occlusion location in the distal vasculature (M2 or more distal) and (2) direct thrombus aspiration attempt with an OLC. Demographic, clinical, and procedural data were recorded.
RESULTS: Eight patients were included for analysis (Table 1). The median admission NIHSS was 17 (IQR 13-23.3). Occlusion locations included left M2 (6/8), right M2 (1/8), and left M3 (1/8). The OLCs employed included the Stryker Catalyst 6 (5/8), Penumbra Velocity (2/8), and the MicroVention Sofia Plus (1/8). Direct thrombus aspiration was successful in 50% (4/8) of cases, though final TICI 2b-3 was achieved in all patients. There were no instances of symptomatic intracranial hemorrhage. Median NIHSS at discharge was 5 (IQR 0.8, 15).
CONCLUSIONS: Aspiration thrombectomy with OLCs may be safe and effective in the distal vasculature. In light of the recent FDA warning regarding their use, further evaluation of OLCs in this capacity is warranted.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app